Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Oct 14, 2022 10:18am
121 Views
Post# 35024601

RE:RE:RE:RE:RE:RE:Finally listened to call

RE:RE:RE:RE:RE:RE:Finally listened to call

I'm not say enrolment is going fast or slow. I'm saying it's rate is most likely baked into the protocol. I think we can understand it was in the dose escalation and I can see every reason why it still is based on managing toxicity risk. Your nurses venting their frustration might in fact be a sign of that.


juniper88 wrote: @Joe.  How many people on this board have actual experience with the TH1902 trial?  It is basically me,and maybe Rusty a small amount with his cousin

They are expanding into other countries because it is worthwhile doing.  That in itself was a go/no to decision.  I had the discussion with Christian about why Canada was not going to have sites initially.  It has mostly to do with paperwork (which is very cumbersome in Canada) and Thera wanting to get things done as fast as possible. Involving Canada and the EU for the 1b part of the trial was always in the plans from the beginning.  Nothing to do with enrollment.  But now it seems it is worthwhile to continue with the original plan to expand to Canada and the EU, which won't be cheap.

Why do you assume that Christian does not meet with the lead investigators?  He meets with them weekly.  I spoke to many nurses about the TH1902 trial, they were actually frustrated that they could not get more patients on during the 1a portion of the trial.  But they are very happy to be able to get more patients on now.  I don't believe enrollment is an issue.  It is just an assumption that people here are making to come up for explanations as to why a big efficacy announcement has not been made. Well this is Thera, get used to it.  They will communicate when they feel like it.

 

Joemare wrote: When you add countries, it means there's an issue with patient accrual.  So late in the game to involve Canada and the EU is somewhat due to a lack of a) competency in clinical trial mgmt and b)executive leadership.

Are they using a CRO to conduct the clinical trial? If not, why not??? If so, fire them.  Use a better one. Tons out there with P.I knowledge

They need to get the prinicpal investigators, the study coordinators, nurses pumped up to recruit patients. How many times did the VP and P meet with these clinical invesigators???




<< Previous
Bullboard Posts
Next >>